Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 264

Showing 1-25 of 264 citing articles:

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Ronza Najjar‐Debbiny, Naomi Gronich, Regina Weber, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e342-e349
Open Access | Times Cited: 442
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 267
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 163
SARS‐CoV‐2 variants and vulnerability at the global level
Vivek P. Chavda, Aayushi Patel, Darsh D. Vaghasiya
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2986-3005
Open Access | Times Cited: 110
SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
Yifei Guo, Jiajia Han, Yao Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 103
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
Jim Baggen, Maarten Jacquemyn, Leentje Persoons, et al.
Cell (2023) Vol. 186, Iss. 16, pp. 3427-3442.e22
Open Access | Times Cited: 101
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 96
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Kai S. Yang, Sunshine Z. Leeuwon, Shiqing Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8686-8698
Open Access | Times Cited: 95
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Steven Lim, Chee Peng Hor, Kim Heng Tay, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 4, pp. 426-426
Open Access | Times Cited: 90
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
Jiao Liu, Xiaojun Pan, Sheng Zhang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 33, pp. 100694-100694
Open Access | Times Cited: 90
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 80
Xuanfei Baidu formula alleviates impaired mitochondrial dynamics and activated NLRP3 inflammasome by repressing NF-κB and MAPK pathways in LPS-induced ALI and inflammation models
Zhenhao Li, Haitao Pan, Jihong Yang, et al.
Phytomedicine (2022) Vol. 108, pp. 154545-154545
Open Access | Times Cited: 70
Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
Saoussen Ben Abdallah, Yosra Mhalla, Imen Trabelsi, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 2, pp. 185-191
Open Access | Times Cited: 50
Pathophysiological mechanisms of thrombosis in acute and long COVID-19
Haijiao Jing, Xiaoming Wu, Mengqi Xiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 50
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 45
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
Luca Cegolon, Riccardo Pol, Omar Simonetti, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 721-721
Open Access | Times Cited: 36
Chemical synthesis of oligosaccharides and their application in new drug research
Zhimin Lv, Hongyu Liu, Huifang Hao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115164-115164
Open Access | Times Cited: 23
SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
Zeinab Mohseni Afshar, Ali Tavakoli Pirzaman, Bardia Karim, et al.
Diagnostics (2023) Vol. 13, Iss. 3, pp. 559-559
Open Access | Times Cited: 23
Scalable Preparation of Ultraselective and Highly Permeable Fully Aromatic Polyamide Nanofiltration Membranes for Antibiotic Desalination
Haohao Liu, Lijun Liang, Feng Tian, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 23
Closed Access | Times Cited: 9
Predicting the hub interactome of COVID-19 and oral squamous cell carcinoma: uncovering ALDH-mediated Wnt/β-catenin pathway activation via salivary inflammatory proteins
Pradeep Kumar Yadalam, Deepavalli Arumuganainar, Prabhu Manickam Natarajan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
Ranran Sun, Haiyu Wang, Junyi Sun, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Fluorine in Medicinal Chemistry: In Perspective to COVID-19
Cheng Zhang
ACS Omega (2022) Vol. 7, Iss. 22, pp. 18206-18212
Open Access | Times Cited: 36
Respiratory Tract Infections in Diabetes – Lessons From Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity
Amnah Al-Sayyar, Katina D. Hulme, Ronan Thibaut, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 30
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?
Sheeba Saifi, Varsha Ravi, Sparsh Sharma, et al.
Genomics (2022) Vol. 114, Iss. 5, pp. 110466-110466
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top